ScripLeo Pharma has had a busy start to 2025 on the business development front but its latest deal, a licensing pact for Shanghai Junshi Biosciences' PD-1 antibody toripalimab, has raised a few eyebrows. T
ScripLEO Pharma A/S may have suffered a setback in the clinic this summer, with a rare skin disease drug failing in Phase III, but the Danish dermatology specialist has enjoyed a strong first half of 2024